---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020466"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:18:28.779326+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyell reports Q1 net loss $60.7M; cash $526.3M; LYL797 data due this quarter

## Summary
- Net loss $60.7M vs $67.0M YoY; non-GAAP net loss $37.5M vs $44.8M.
- Cash, equivalents and securities $526.3M; expected to fund operations into 2027.
- Initial Phase 1 data for LYL797 (ROR1 CAR T) expected this quarter from ≥20 patients.
- LYL845 (TIL) Phase 1 data expected H2 2024; LYL119 IND submission expected this quarter.
- R&D expenses $43.2M vs $44.6M; G&A $13.5M vs $19.3M.

## SEC filing metadata
- accession: 0001628280-24-020466
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/lyel-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020466
- JSON: https://secwatch.observer/filing/0001628280-24-020466.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020466.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $60.7 million.
  - Period: the quarter ended March 31, 2024
  - Net income: net loss of $60.7 million
  - Result: reported results
  source text: On May 6, 2024, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm
- Earnings Releases
  Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $60.7 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: net loss of $60.7 million
  - Result: reported results
  source text: Lyell reported a net loss of $60.7 million for the first quarter ended March 31, 2024, compared to a net loss of $67.0 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.